Mylan (NASDAQ:MYL) was upgraded by BidaskClub from a “buy” rating to a “strong-buy” rating in a research note issued to investors on Tuesday.

Several other analysts have also commented on the stock. Zacks Investment Research lowered shares of Mylan from a “buy” rating to a “hold” rating in a research report on Wednesday, November 8th. Cantor Fitzgerald set a $34.00 price target on shares of Mylan and gave the company a “hold” rating in a research report on Tuesday, October 31st. Mizuho reissued a “buy” rating and set a $37.00 price target on shares of Mylan in a research report on Tuesday, October 24th. Royal Bank of Canada increased their price target on shares of Mylan from $32.00 to $37.00 and gave the company a “sector perform” rating in a research report on Tuesday, November 7th. Finally, BTIG Research increased their price target on shares of Mylan from $42.00 to $45.00 and gave the company a “buy” rating in a research report on Wednesday, October 4th. One analyst has rated the stock with a sell rating, seven have issued a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $42.41.

Shares of Mylan (NASDAQ MYL) opened at $41.67 on Tuesday. Mylan has a one year low of $29.39 and a one year high of $45.87. The firm has a market cap of $21,736.40, a PE ratio of 8.62, a P/E/G ratio of 2.22 and a beta of 1.38. The company has a quick ratio of 0.95, a current ratio of 1.46 and a debt-to-equity ratio of 1.05.

Mylan (NASDAQ:MYL) last released its quarterly earnings data on Monday, November 6th. The company reported $1.10 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.20 by ($0.10). Mylan had a return on equity of 20.63% and a net margin of 7.28%. The business had revenue of $2.99 billion during the quarter, compared to analysts’ expectations of $3.09 billion. During the same period last year, the company earned $1.38 earnings per share. The firm’s revenue was down 2.3% compared to the same quarter last year. analysts anticipate that Mylan will post 4.56 EPS for the current year.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Meeder Asset Management Inc. lifted its position in shares of Mylan by 76.9% during the 3rd quarter. Meeder Asset Management Inc. now owns 3,393 shares of the company’s stock valued at $106,000 after buying an additional 1,475 shares in the last quarter. BT Investment Management Ltd purchased a new position in shares of Mylan during the 3rd quarter valued at approximately $142,000. Global X Management Co. LLC lifted its position in shares of Mylan by 59.2% during the 2nd quarter. Global X Management Co. LLC now owns 4,801 shares of the company’s stock valued at $186,000 after buying an additional 1,786 shares in the last quarter. Doliver Capital Advisors LP purchased a new position in shares of Mylan during the 2nd quarter valued at approximately $201,000. Finally, Sheaff Brock Investment Advisors LLC purchased a new position in shares of Mylan during the 2nd quarter valued at approximately $210,000. 74.90% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: This piece of content was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another website, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/12/19/mylan-myl-upgraded-to-strong-buy-by-bidaskclub.html.

Mylan Company Profile

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.

Analyst Recommendations for Mylan (NASDAQ:MYL)

Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.